HOME >> BIOLOGY >> NEWS
How cold! New partnership to use chilled neutrons

nnsylvania, Rice University, Carnegie Mellon University, the Duke University Medical Center and the Los Alamos National Laboratory.

Neutrons are non-destructive, highly penetrating probes, valuable for studying changes in membranes over time. Because they behave like tiny waves of energy, neutrons also make excellent rulers. Depending on temperature, the length of the neutron ruler can be tuned over a range spanning from roughly the size of a single atom to the size of a molecule composed of hundreds or thousands of atoms.

The CNBT team is now building a unique instrument with dual capabilities: diffractometry and reflectometry. It will detect neutrons that are reflected or otherwise scattered after striking membrane samples. Reflected or diffracted neutrons will provide information on the location, orientation, size and composition of membrane components. In addition, the team is upgrading another instrument useful for studying large molecules--a small-angle neutron spectrometer--that will be shared with researchers in other fields.

The instruments are scheduled to be completed in 2003. They will provide cell membrane scientists with access to powerful technologies well beyond the resources of individual researchers.

"This is an extremely hard problem," says NIST biophysicist Susan Krueger, a CNBT collaborator interested in enhancing neutron-based measurement capabilities. "We'll be testing lots of membrane systems and lots of different approaches to capturing the data we need."

The job facing cell-membrane researchers is akin to assembling an intricate and dynamic three-dimensional puzzle. Many pieces have complex contours that not only are unknown but also are subject to change.

"No single instrument or set of techniques can supply all the missing information," says NIST's Krueger. In addition to neutron scattering, an arra
'"/>

Contact: Mark Bello (NIST)
mark.bello@nist.gov
301-975-3776
National Institute of Standards and Technology (NIST)
25-Feb-2002


Page: 1 2 3

Related biology news :

1. Unique partnership between UH, FDA opens path for scientific exchange
2. $5 million grant funds partnership, studies of minority-based issues in reproductive health
3. Studies show success of Mectizan partnerships
4. Pioneering discoveries, pursuing new knowledge, fostering partnerships
5. Childrens Memorial, TGen announce partnership
6. Conservation International & Starbucks expand partnership, launch Verde Ventures loan program
7. $62-million partnership to revolutionize ocean research
8. Cancer patient-physician partnership
9. AF&PA to announce EPA partnership and roll out 55% paper recovery goal
10. UN Foundation & Conservation International forge $15M partnership to protect global biodiversity
11. Starbucks-Conservation Intl. partnership awarded at World Summit

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: How cold New partnership use chilled neutrons

(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... of the planet,s leading questions is how to produce ... variable climate. The Food and Agriculture Organization of the ... over the next 40 years to feed a growing ... the necessary rise in food production. Plants—grains, cereals, ... supporting livestock. Current research must tap into our ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
(Date:10/22/2014)... YORK , Oct. 22, 2014 Nuvilex, ... Federation, approximately 400 million people worldwide are living with ... million people by 2030.  The global market for diabetes ... 2012 approximately 330,000 people worldwide died from pancreatic cancer.  ... death due to cancer in the United ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: